To appraise the clinical and cost effectiveness of cannabidiol within its marketing authorisation for treating seizures caused by tuberous sclerosis complex.
 
Status Awaiting development
Decision None selected
Process STA 2018
ID number 1416

Provisional Schedule

Committee meeting: 1 15 September 2022
Committee meeting: 2 10 November 2022
Expected publication 23 November 2022

Project Team

Project lead Daniel Davies

Email enquiries

Stakeholders

Companies sponsors GW Pharmaceuticals (cannabidiol)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Gene People
  Tuberous Sclerosis Association
  Young Epilepsy
Professional groups Association of British Neurologists
  British Society for Genetic Medicine
  Royal College of General Practitioners
  Royal College of Physicians
Associated public health groups None
Comparator companies GlaxoSmithKline (lamotrigine)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
18 January 2022 Invitation to participate
03 September 2021 We recently contacted all stakeholders for the appraisal of cannabidiol for treating seizures caused by tuberous sclerosis complex regarding a delay to this topic for operational reasons. Cannabidiol for treating seizures caused by tuberous sclerosis complex has now been rescheduled into the work programme. The appraisal is due to start mid-January 2022 and will be discussed at committee in mid-September 2022. The new timelines are subject to the work programme capacity and we will continue to review our plans in collaboration with the company and update our stakeholders accordingly.
18 June 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
11 June 2021 (14:00) Scoping workshop
15 April 2021 - 14 May 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual